MK-3866
Total Payments
$2.8M
Transactions
106
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2019 | $599,117 | 8 | 0 |
| 2018 | $2.0M | 69 | 0 |
| 2017 | $224,288 | 29 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $2.8M | 106 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Two Part, Double-Blinded, Multiple Dose Clinical Trial to Study the Safety, Tolerability and Pharmacokinetics of MK-3866 alone or in Combination with Relebactam and Imipenem,Cilastatin or Relebactam and Cefepime in Healthy Adult Subjects | Merck Sharp & Dohme Corporation | $830,478 | 0 |
| A 2-Part, Open-Label Trial to Evaluate the Pharmacokinetics of MK-3866 Following the Administration of a Single IV dose to Subjects with Mild, Moderate and Severe Renal Impairment, and End Stage Renal Disease. | Merck Sharp & Dohme Corporation | $644,002 | 0 |
| Examine the pharmacodynamics of the beta-lactamase inhibitor MK-3866 in combination with the human-simulated exposures of cefepime and cefepime,relebactam humanized combination against a range of Pseudomonas aeruginosa and Enterobacteriaceae isolates expressing various beta-lactamases serine and metallo- beta-lactamases in the murine thigh infection model. | Merck Sharp & Dohme Corporation | $535,039 | 0 |
| A Multiple Dose Study to Evaluate the Intrapulmonary Pharmacokinetics of MK-3866 Dosed in Combination with Relebactam and Imipenem,Cilastatin in Healthy Subjects. | Merck Sharp & Dohme Corporation | $349,342 | 0 |
| A Study to Assess the Pharmacokinetics of Dabigatran, Midazolam, Atorvastatin, Rosuvastatin, and Pitavastatin Administered as Microdoses in the Presence and Absence of Rifampin in Subjects with Varying Degrees of Renal Impairment. | Merck Sharp & Dohme Corporation | $245,675 | 0 |
| An Open-Label Trial to Evaluate the Safety, Tolerability and Pharmacokinetics of the Co-infusion of a Single Intravenous Dose of MK-3866 with a Single Intravenous Dose of Relebactam REL, MK-7655 in Healthy Adult Subjects | Merck Sharp & Dohme Corporation | $172,620 | 0 |
| A Single-Dose, Three-Period, Randomized, Open-Label, Crossover, Drug Interaction Study to Evaluate the Pharmacokinetics of the Intravenous Coadministration of MK-3866 and Relebactam with Imipenem,Cilastatin and Cefepime in Healthy Adult Subjects. | Merck Sharp & Dohme Corporation | $41,961 | 0 |
| A 2 Part, Open-Label Study to Investigate the Single-Dose Pharmacokinetics of MK-3866 when Administered to Subjects with Moderate and Severe Hepatic Impairment as 30 Minute IV Infusions | Merck Sharp & Dohme Corporation | $924.02 | 0 |
| A Randomized, Double-Blind, Placebo-Controlled, Fixed-Sequence, 2-Panel, Drug Interaction Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of the Intravenous Coadministration of MK-3866 and Relebactam with Imipenem,Cilastatin and Cefepime in Healthy Adult Subjects. | Merck Sharp & Dohme Corporation | $59.96 | 0 |
Top Doctors Receiving Payments for MK-3866
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Hialeah, FL | $2.8M | 106 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $2.8M
- Total Doctors 0
- Transactions 106
About MK-3866
MK-3866 is a drug associated with $2.8M in payments to 0 healthcare providers, recorded across 106 transactions in the CMS Open Payments database. The primary manufacturer is Merck Sharp & Dohme Corporation.
Payment data is available from 2017 to 2019. In 2019, $599,117 was paid across 8 transactions to 0 doctors.
The most common payment nature for MK-3866 is "Unspecified" ($2.8M, 100.0% of total).
MK-3866 is associated with 9 research studies, including "A Two Part, Double-Blinded, Multiple Dose Clinical Trial to Study the Safety, Tolerability and Pharmacokinetics of MK-3866 alone or in Combination with Relebactam and Imipenem,Cilastatin or Relebactam and Cefepime in Healthy Adult Subjects" ($830,478).